After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

We just can't get there. Maybe they see something we don't see.

This is half the savings that Pfizer achieved with its recently announced program.

The U.S. case is more important because of the economic implications, ... It [the U.K. ruling] is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

The U.S. case is more important because of the economic implications. It (the U.K. ruling) is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

Schering-Plough shares are most likely to be impacted by first quarter 2006 results.